(98 days)
No
The device description clearly states it is a rapid chromatographic immunoassay based on antigen-antibody immunochemistry and can be performed without an instrument. There is no mention of AI, ML, image processing, or any computational analysis of the results. The results are interpreted visually based on the presence or absence of colored lines.
No.
The device is for the qualitative detection of drugs in urine, which is a diagnostic purpose, not a therapeutic one.
Yes
This device is intended for the qualitative and simultaneous detection of drugs in human urine, which serves to identify the presence of substances in a sample, a key characteristic of a diagnostic device.
No
The device description clearly states it is a "rapid chromatographic immunoassay" and a "competitive binding, lateral flow immunochromatographic assay," which are hardware-based test methods. It also mentions "membrane wicking" and the appearance of "colored-line[s]," indicating a physical test strip.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that the device is for the "qualitative and simultaneous detection of two to six drugs in a variety of combinations in human urine." This involves testing a sample taken from the human body (urine) to provide information about a person's health status (presence of drugs).
- Device Description: The description details a "rapid chromatographic immunoassay" that utilizes antibodies to detect specific substances (drugs) in a biological sample (urine). This is a common method used in IVD devices.
- Clinical Evaluation: The document describes a clinical evaluation using "clinical urine specimens" to compare the device's performance against predicate devices and a reference method (GC/MS analysis). This type of testing is characteristic of the validation process for IVD devices.
- Comparison to Predicate Devices: The device is compared to previously FDA-cleared devices, which are also IVDs (as indicated by their K numbers and names like "ACON AMP One Step Amphetamine Test Strip").
All of these points align with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The ACON® One Step Multi-Drug Multi-Line Screen Test Card and Test Device are rapid chromatographic immunoassays for the qualitative and simultaneous detection of two to six drugs in a variety of combinations in human urine samples. The designated cut-off concentrations for these drugs are as follows: Amphetamine at 1,000 ng/ml, Cocaine at 300 ng/ml, Methamphetamine at 1,000 ng/ml, Opiates at 2,000 ng/ml, Marijuana at 50 ng/ml and Phencyclidine at 25 ng/ml. They are intended for healthcare professionals including professionals at the point of care sites.
Product codes
DKZ, DIO, LDJ, DJG, LCM, LAF
Device Description
The ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device are competitive binding, lateral flow immunochromatographic assays for the qualitative and simultaneous detection of Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine in urine samples. The test is based on the principle of antigen-antibody immunochemistry. It utilizes mouse monoclonal antibodies to selectively detect elevated levels of Amphetamine, Methamphetamine, Cocaine, Opiates, THC and PCP in urine at the cut-off concentrations of 1,000 ng/ml (AMP), 1,000 ng/ml (mAMP), 300 ng/mL (COC), 2,000 ng/ml (OPI), 50 ng/ml (THC) and 25 ng/ml (PCP). These tests can be performed without the use of an instrument.
A positive urine specimen will not generate a colored-line for the specific drug tested in the designated test region. A negative urine specimen or a urine specimen containing of Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine at the concentrations below the designated cut-off levels will generate a colored-line in the designated test region for the drug. To serve as a procedural control, a colored-line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professionals including professionals at the point of care sites.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A clinical evaluation was conducted using clinical urine specimens. This evaluation compared the test results between ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device versus previously FDA-cleared Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine Single tests; as well as against data obtained from the customary GC/MS analysis. Over 1,000 clinical specimens were employed including approximately 10% of the samples with drug concentrations in the -25% to +25% cut-off range.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Study Type: Clinical evaluation comparing test performance against previously FDA-cleared single tests and GC/MS analysis.
Sample Size: Over 1,000 clinical specimens.
Key Results:
Comparison against single tests (example for ACON One Step Multi-Drug Multi-Line Screen Test Card):
- AMP: Positive Agreement 129/129 (>99%), Negative Agreement 172/172 (>99%), Overall Agreement 301/301 (>99%)
- COC: Positive Agreement 112/112 (>99%), Negative Agreement 186/187 (99%), Overall Agreement 298/299 (99%)
- mAMP: Positive Agreement 121/122 (99%), Negative Agreement 174/174 (>99%), Overall Agreement 295/296 (99%)
- OPI: Positive Agreement 131/133 (98%), Negative Agreement 164/164 (>99%), Overall Agreement 295/297 (99%)
- THC: Positive Agreement 124/124 (>99%), Negative Agreement 175/176 (99%), Overall Agreement 299/300 (99%)
- PCP: Positive Agreement 71/72 (99%), Negative Agreement 160/160 (>99%), Overall Agreement 231/232 (99%)
Comparison against GC/MS Analysis (example for ACON One Step Multi-Drug Multi-Line Screen Test Card):
- AMP: Positive Agreement 129/136 (95%), Negative Agreement 164/165 (99%), Overall Agreement 293/301 (97%)
- COC: Positive Agreement 112/118 (95%), Negative Agreement 180/181 (99%), Overall Agreement 292/299 (98%)
- mAMP: Positive Agreement 121/134 (90%), Negative Agreement 162/162 (>99%), Overall Agreement 283/296 (96%)
- OPI: Positive Agreement 130/131 (99%), Negative Agreement 164/166 (99%), Overall Agreement 294/297 (99%)
- THC: Positive Agreement 116/122 (95%), Negative Agreement 169/178 (95%), Overall Agreement 285/300 (95%)
- PCP: Positive Agreement 70/78 (90%), Negative Agreement 153/154 (99%), Overall Agreement 223/232 (96%)
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
- ACON One Step Multi-Drug Multi-Line Screen Test Card vs. ACON Single Tests (Agreement):
- AMP: Positive Agreement >99%, Negative Agreement >99%, Overall Agreement >99%
- COC: Positive Agreement >99%, Negative Agreement 99%, Overall Agreement 99%
- mAMP: Positive Agreement 99%, Negative Agreement >99%, Overall Agreement 99%
- OPI: Positive Agreement 98%, Negative Agreement >99%, Overall Agreement >99%
- THC: Positive Agreement >99%, Negative Agreement 99%, Overall Agreement 99%
- PCP: Positive Agreement 99%, Negative Agreement >99%, Overall Agreement 99%
- ACON One Step Multi-Drug Multi-Line Screen Test Device vs. ACON Single Tests (Agreement):
- AMP: Positive Agreement >99%, Negative Agreement >99%, Overall Agreement >99%
- COC: Positive Agreement >99%, Negative Agreement >99%, Overall Agreement >99%
- mAMP: Positive Agreement >99%, Negative Agreement >99%, Overall Agreement >99%
- OPI: Positive Agreement >99%, Negative Agreement >99%, Overall Agreement >99%
- THC: Positive Agreement >99%, Negative Agreement >99%, Overall Agreement >99%
- PCP: Positive Agreement 99%, Negative Agreement >99%, Overall Agreement 99%
- ACON One Step Multi-Drug Multi-Line Screen Test Card vs. GC/MS Analysis (Agreement):
- AMP: Positive Agreement 95%, Negative Agreement 99%, Overall Agreement 97%
- COC: Positive Agreement 95%, Negative Agreement 99%, Overall Agreement 98%
- mAMP: Positive Agreement 90%, Negative Agreement >99%, Overall Agreement 96%
- OPI: Positive Agreement 99%, Negative Agreement 99%, Overall Agreement 99%
- THC: Positive Agreement 95%, Negative Agreement 95%, Overall Agreement 95%
- PCP: Positive Agreement 90%, Negative Agreement 99%, Overall Agreement 96%
- ACON One Step Multi-Drug Multi-Line Screen Test Device vs. GC/MS Analysis (Agreement):
- AMP: Positive Agreement 94%, Negative Agreement 99%, Overall Agreement 97%
- COC: Positive Agreement 95%, Negative Agreement 99%, Overall Agreement 98%
- mAMP: Positive Agreement 90%, Negative Agreement >99%, Overall Agreement 95%
- OPI: Positive Agreement 99%, Negative Agreement 99%, Overall Agreement 99%
- THC: Positive Agreement 95%, Negative Agreement 96%, Overall Agreement 95%
- PCP: Positive Agreement 90%, Negative Agreement 99%, Overall Agreement 96%
Predicate Device(s)
K011673, K011672, K010841, K011353, K003557, K011730
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.3100 Amphetamine test system.
(a)
Identification. An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.(b)
Classification. Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
8. SUMMARY OF 510(k) SAFETY AND EFFECTIVENESS
This summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
KO20313 The Assigned 510(k) number is
Submitter:
ACON Laboratories, Inc. 4108 Sorrento Valley Boulevard San Diego, California 92121
Tel.: 858-535-2030 Fax: 858-535-2038
Date: January 28, 2002
Contact Person: Edward Tung, Ph.D.
Product Names:
ACON One Step Multi-Drug Multi-Line Screen Test Card
ACON One Step Multi-Drug Multi-Line Screen Test Device
Common Name:
Immunochromatographic test for the simultaneously qualitative detection of Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine in urine.
Device Classification:
The ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device are similar to other FDA-cleared devices for the qualitative and simultaneous detection of Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine in urine specimens. These tests are used to provide a preliminary analytical result only. Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine test systems have been classified as Class II devices with moderate complexity.
Classification Name:
Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine test system
1
Intended Use:
The ACON® One Step Multi-Line Screen Test Card and Test Device are rapid chromatographic immunoassays for the qualitative and simultaneous detection of two to six drugs in a variety of combinations in human urine samples. The designated cut-off concentrations for these drugs are as follows: Amphetamine at 1,000 ng/ml, Cocaine at 300 ng/ml, Methamphetamine at 1,000 ng/ml, Opiates at 2,000 ng/ml, Marijuana at 50 ng/ml and Phencyclidine at 25 ng/ml. They are intended for healthcare professionals including professionals at the point of care sites.
Description:
The ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device are competitive binding, lateral flow immunochromatographic assays for the qualitative and simultaneous detection of Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine in urine samples. The test is based on the principle of antigen-antibody immunochemistry. It utilizes mouse monoclonal antibodies to selectively detect elevated levels of Amphetamine, Methamphetamine, Cocaine, Opiates, THC and PCP in urine at the cut-off concentrations of 1,000 ng/ml (AMP), 1,000 ng/ml (mAMP), 300 ng/mL (COC), 2,000 ng/ml (OPI), 50 ng/ml (THC) and 25 ng/ml (PCP). These tests can be performed without the use of an instrument.
A positive urine specimen will not generate a colored-line for the specific drug tested in the designated test region. A negative urine specimen or a urine specimen containing of Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine at the concentrations below the designated cut-off levels will generate a colored-line in the designated test region for the drug. To serve as a procedural control, a colored-line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.
Predicate Devices:
ACON™ of Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine Single Drug Test strips were used as the predicate devices for the ACON® One Step Multi-Drug Multi-Line Screen Test Card and Test Device to compare their performance with clinical urine specimens.
510(k) Number for these predicate devices are:
| ACON AMP One Step Amphetamine Test Strip | K011673 |
|---|---|
| ACON mAMP One Step Methamphetamine Test Strip | K011672 |
| ACON COC One Step Cocaine Test Strip | K010841 |
| ACON OPI One Step Opiates Test Strip | K011353 |
| ACON THC One Step Marijuana Test Strip | K003557 |
| ACON PCP One Step Phencyclidine Test Strip | K011730 |
2
Comparison to a Predicate Device:
A comparison of the features of the ACON™ One Step Multi-Line Screen Test Card and Test Device versus the ACON™ Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine Single Tests is shown below:
- Both tests are assays intended for the qualitative detection of Amphetamine, Cocaine, . Methamphetamine, Opiates, Marijuana, and Phencyclidine in urine samples.
- Both tests are intended as a screening method that provides a preliminary analytical test result. .
- Both tests are immunochromatographic, lateral flow assays for the rapid detection of . Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine with a visual, qualitative end result, while ACON Multi-Drug Multi-Line Test detects 2 to 6 of the above drugs simultaneously.
- Both tests utilize the same basic immunoassay principles that rely on antigen/ antibody ● interactions to indicate a positive or negative result.
- Both tests have the same cut-off for each drug test. .
Safety and Effectiveness Data:
Accuracy
A clinical evaluation was conducted using clinical urine specimens. This evaluation compared the test results between ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device versus previously FDA-cleared Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine Single tests; as well as against data obtained from the customary GC/MS analysis. Over 1,000 clinical specimens were employed including approximately 10% of the samples with drug concentrations in the -25% to +25% cut-off range. The comparisons of data obtained from this study yielded the following results:
3
ACON One Step Multi-Drug Multi-Line Screen Test Card
vs.
| ACON Test Card | Positive Agreement | Negative Agreement | Overall Agreement |
|---|---|---|---|
| AMP | 129/129=>99% | ||
| (97% - 99%)* | 172/172=>99% | ||
| (98% - 99%)* | 301/301=>99% | ||
| (98% - 99%)* | |||
| COC | 112/112=>99% | ||
| (97% - 99%)* | 186/187=99% | ||
| (97% - 99%)* | 298/299=99% | ||
| (98% - 99%)* | |||
| mAMP | 121/122=99% | ||
| (96% - 99%)* | 174/174=>99% | ||
| (98% - 99%)* | 295 / 296=99% | ||
| (98%-99%) | |||
| OPI | 131/133=98% | ||
| (95% - 99%)* | 164/164=>99% | ||
| (98% - 99%) | 295/297 =>99% | ||
| (97%-99%) | |||
| THC | 124/124=>99% | ||
| (97% - 99%)* | 175/176=99% | ||
| (97% - 99%)* | 299/300=99% | ||
| (98%-99%)* | |||
| PCP | 71/72=99% | ||
| (93% - 99%)* | 160/160=>99% | ||
| (98%-99%)* | 231/232=99% | ||
| (97% - 99%)* |
Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine Single Tests:
- 95% Confidence Interval
ACON One Step Multi-Drug Multi-Line Screen Test Device vs.
Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine Single Test:
| ACON Test Device | Positive Agreement | Negative Agreement | Overall Agreement |
|---|---|---|---|
| AMP | 129/129=>99% | ||
| (97%-99%)* | 172/172=>99% | ||
| (98%-99%) | 301/301=>99% | ||
| (98%-99%)* | |||
| COC | 112/112=>99% | ||
| (97%-99%)* | 186/187=>99% | ||
| (97%-99%)* | 298/299=>99% | ||
| (98%-99%)* | |||
| mAMP | 121/121=>99% | ||
| (97% - 99%)* | 175/175=>99% | ||
| (98%-99%)* | 296 / 296 =>99% | ||
| (98%-99%)* | |||
| OPI | 132/133=>99% | ||
| (96% - 99%)* | 164/164=>99% | ||
| (98%-99%) | 296/297=>99% | ||
| (98%-99%)* | |||
| THC | 124/124 =>99% | ||
| (97% - 99%)* | 175/176=>99% | ||
| (98%-99%)* | 299 / 300=>99% | ||
| (98%-99%)* | |||
| PCP | 71/72 = 99% | ||
| (95% - 99%)* | 160/160=>99% | ||
| (98%-99%)* | 231/232 = 99% | ||
| (97% - 99%)* |
- 95% Confidence Interval
4
Clinical study results of ACON One Step Multi-Line Screen Test Card and Test Device are compared to GC/MS analysis data:
The GC/MS cut-off levels for each of the six drugs tested are as following:
| Amphetamine | 1,000 ng/ml |
|---|---|
| Cocaine | 300 ng/ml |
| Methamphetamine | 1,000 ng/ml |
| Opiate | 2,000 ng/ml |
| Marijuana | 50 ng/ml |
| Phencyclidine | 25 ng/ml |
Samples with drug concentration above the cut-off level were considered presumptive positive and concentrations below the cut-off are considered negative.
ACON One Step Multi-Drug Multi-Line Screen Test Card vs. GC/MS Analysis
| ACON Test Card | Positive Agreement | Negative Agreement | Overall Agreement |
|---|---|---|---|
| AMP | 129/136=95% | ||
| (90% - 98%)* | 164/165=99% | ||
| (97% - 99%)* | 293/301 = 97% | ||
| (95% - 99%)* | |||
| COC | 112/118 = 95% | ||
| (89% - 98%)* | 180/181 = 99% | ||
| (97% - 99%)* | 292/299 = 98% | ||
| (95% - 99%)* | |||
| mAMP | 121/134 = 90% | ||
| (84% - 94%)* | 162/162 = >99% | ||
| (98% - 100%)* | 283 / 296 = 96% | ||
| (93% - 98%)* | |||
| OPI | 130/131 = 99% | ||
| (96% - 99%)* | 164/166 = 99% | ||
| (96% - 99%)* | 294/297 = 99% | ||
| (97% - 99%)* | |||
| THC | 116/122 = 95% | ||
| (90% - 98%)* | 169/178 = 95% | ||
| (91% - 98%)* | 285 / 300 = 95% | ||
| (92% - 97%) | |||
| PCP | 70/78 = 90% | ||
| (81% - 95%)* | 153/154 = 99% | ||
| (96% - 99%)* | 223/232 = 96% | ||
| (93% - 98%)* |
- 95% Confidence Interval
5
| ACON Test Device | Positive Agreement | Negative Agreement | Overall Agreement |
|---|---|---|---|
| AMP | 128/136=94% | ||
| (89% - 97%) | 164/165=99% | ||
| (97% - 99%) | 292/301 = 97% | ||
| (94% - 99%)* | |||
| COC | 112/118 = 95% | ||
| (89% - 98%)* | 180/181 = 99% | ||
| (97% - 99%)* | 292/299 = 98% | ||
| (95% - 99%)* | |||
| mAMP | 120/134 = 90% | ||
| (83% - 94%)* | 162/162 =>99% | ||
| (98% - 100%) | 282 / 296 = 95% | ||
| (92% - 97%)* | |||
| OPI | 130/131 = 99% | ||
| (96% - 100%) | 164/166 = 99% | ||
| (96% - 99%)* | 294/297 = 99% | ||
| (97% - 99%)* | |||
| THC | 116/122 = 95% | ||
| (90% - 98%)* | 170/178 = 96% | ||
| (91% - 98%)* | 286 / 300 = 95% | ||
| (92% - 97%)* | |||
| PCP | 70/78 = 90% | ||
| (81% - 95%)* | 152/154 = 99% | ||
| (96% - 99%)* | 222/232 = 96% | ||
| (92% - 98%)* |
ACON One Step Multi-Drug Multi-Line Screen Test Device vs. GC/MS Analysis
- 95% Confidence Interval
Conclusion:
Clinical study results demonstrate the substantial equivalency between the ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device and the Amphetamine, Methamphetamine, Cocaine, Opiates, THC and PCP single tests, which has already being cleared by FDA and marketed in the United States. It is also demonstrated that these tests are safe and effective in detecting Amphetamine, Cocaine, Methamphetamine, Opiates, Marijuana, and Phencyclidine at the following cut-off concentrations: Amphetamine 1,000 ng/ml, Cocaine 300 ng/ml, Methamphetamine 1,000 ng/ml, Opiates 2,000 ng/ml, THC 50 ng/ml and PCP 25 ng/ml. The physician's office laboratory POL study demonstrated that these tests are also suitable for use by professional at point-of-care site.
6
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/6/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States of America. The seal features a stylized caduceus, a symbol often associated with medicine and healthcare, with three parallel lines forming the staff and a snake winding around it. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the caduceus.
Re:
MAY 0 8 2002
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Edward Tung, Ph.D. Director of Regulatory Affairs ACON Laboratories, Inc. 4108 Sorrento Valley Blvd. San Diego, CA 92121
K020313 Trade/Device Names: ACON® One Step Multi-Line Screen Test Card ACON® One Step Multi-Drug Multi-Line Screen Test Device Regulation Number: 21 CFR 862.3100; 21 CFR 862.3250; 21 CFR 862.3870; 21 CFR 862.3650; 21 CFR 862.3610 Regulation Name: Amphetamine test system; Cocaine and cocaine metabolite test System; Cannabinoid test system; Opiate test system; Methamphetamine test system Regulatory Class: Class II; Class II; Class II; Class II, Class II Product Code: DKZ; DIO; LDJ; DJG; LCM; LAF Dated: April 8, 2002 Received: April 12, 2002
Dear Dr. Tung:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
7
Page 2 - .
This letter will allow you to begin marketing your device as described in your 510(k) premarket I nis lotton . The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, (Joase contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
8
INDICATIONS FOR USE 10.
510(k) Number:
ACON® One Step Multi-Drug Multi-Line Screen Test Card Device Name:
ACON® One Step Multi-Drug Multi-Line Screen Test Device
Indications for Use:
The ACON® One Step Multi-Drug Multi-Line Screen Test Card and Test Device are rapid chromatographic immunoassays for the qualitative and simultaneous detection of two to six drugs in a variety of combinations in human urine. The designated cut-off concentrations for these drugs are as follows: Amphetamine at 1,000 ng/ml, Cocaine at 300 ng/ml, Methamphetamine at 1,000 ng/ml, Opiates at 2,000 ng/ml, Marijuana at 50 ng/ml and Phencyclidine at 25 ng/ml. They are intended for healthcare professionals including professionals at the point of care sites.
Lean Cooper
(Division Sign-Off)
Division of Clinical L
510(k) Number. K020313
(Please do not write below this point) Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
Or
Over-The-Counter Use